Sensitive bioassay for determination of fluconazole concentrations in plasma using a Candida albicans mutant hypersusceptible to azoles

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 3, 2001, Pages 696-700

  Marchetti, O ^a   Majcherczyk, P A ^a   Glauser, M P ^a   Bille, J ^a   Moreillon, P ^a   Sanglard, D ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ANIMAL EXPERIMENT; ANTIFUNGAL ACTIVITY; ARTICLE; BIOASSAY; CANDIDA ALBICANS; CANDIDA PSEUDOTROPICALIS; DRUG BLOOD LEVEL; DRUG DETERMINATION; FEMALE; FUNGUS CULTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIFUNGAL AGENTS; AZOLES; BIOLOGICAL ASSAY; CANDIDA ALBICANS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLONY COUNT, MICROBIAL; FEMALE; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, ANIMAL; RATS; RATS, WISTAR;

EID: 0035115550     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.3.696-700.2001     Document Type: Article

References (17)

1. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections
2. A novel multidrug efflux transporter gene of the major facilitator superfamily front Candida albicans (FLUI) conferring resistance to fluconazole
3. Correlation of in vivo fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1
4. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
5. Susceptibility testing of fungi: Current status of correlation of in vitro data with clinical outcome
6. Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses
7. Fluconazole treatment of Candida albicans infection in mice: Does in vitro susceptibility predict in vivo response?
8. Serum level determination of fluconazole by high-performance liquid chromatography and bioassay
9. Pharmacokinetic evaluation of UK-49.858, a melabolically stable triazole antifungal drug, in animals and humans
10. Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans
11. Microtiter broth dilution method for yeast susceptibility testing with validation by clinical outcome
12. Standardization of a fluconazole bioassay and correlation of results to those obtained by high-pressure liquid chromatography
13. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis
14. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole and Candida infections
15. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors
16. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies